IP Library Granted Patent US 11,344,568
Granted Patent B2
US 11,344,568 · App. 16/825,121 · Granted May 31, 2022

Methods and compositions for administration of iron

Inventors: Mary Jane Helenek (Brookville, NY); Marc L. Tokars (Douglassville, PA); Richard P. Lawrence (Calverton, NY)
Assignee: American Regent, Inc.
A61K31/7135A61K31/715A61K31/721C07H23/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,344,568
App. No.
16/825,121
Granted
May 31, 2022
Kind
B2
Abstract

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

Claims (27)

1. A method of treating a disease, disorder, or condition characterized by iron deficiency or dysfunctional iron metabolism resulting in reduced bioavailability of dietary iron, comprising administering to a human subject in need thereof an iron carbohydrate complex in a single dosage of at least 9 mg of elemental iron per kg of body weight, wherein:

a) the iron carbohydrate complex is substantially non-immunogenic, and has substantially no cross reactivity with anti-dextran antibodies; and

b) the iron carbohydrate complex is an iron polyisomaltose complex,

wherein the disease, disorder, or condition is not Restless Leg Syndrome.

2. The method of claim 1 , wherein the polyisomaltose is reduced polyisomaltose.

3. The method of claim 1 , wherein the iron carbohydrate complex has a molecular weight of about 90,000 daltons to about 800,000 daltons.

4. The method of claim 1 , wherein the iron carbohydrate complex has a molecular weight of about 150,000 daltons.

5. The method of claim 1 , wherein the iron carbohydrate complex has a blood half-life of between about 10 hours to about 20 hours.

6. The method of claim 1 , wherein the iron carbohydrate complex has a pH between about 5.0 to about 7.0 and physiological osmolarity.

7. The method of claim 1 , wherein the iron carbohydrate complex is administered in about 15 minutes or less.

8. The method of claim 1 , wherein the single dosage of the iron carbohydrate complex is at least about 0.6 grams of elemental iron.

9. The method of claim 1 , wherein the iron carbohydrate complex is administered parenterally.

10. The method of claim 1 , wherein the disease, disorder, or condition comprises anemia.

11. The method of claim 10 , wherein the anemia comprises iron deficiency anemia.

12. The method of claim 10 , wherein the anemia comprises an iron deficiency anemia associated with chronic blood loss, acute blood loss, pregnancy, childbirth, childhood development, psychomotor and cognitive development in children, breath holding spells, heavy uterine bleeding, menstruation, chronic recurrent hemoptysis, idiopathic pulmonary siderosis, chronic internal bleeding, gastrointestinal bleeding, parasitic infections, chronic kidney disease, dialysis, surgery or acute trauma, chronic ingestion of alcohol, chronic ingestion of salicylates, chronic ingestion of steroids, chronic ingestion of non-steroidal antiinflammatory agents, or chronic ingestion of erythropoiesis stimulating agents.

13. The method of claim 10 , wherein the anemia is of a chronic disease selected from among rheumatoid arthritis, cancer, Hodgkin's leukemia, non-Hodgkin's leukemia, cancer chemotherapy, inflammatory bowel disease, ulcerative colitis thyroiditis, hepatitis, systemic lupus erythematosus, polymyalgia rheumatica, scleroderma, mixed connective tissue disease, Sjogren's syndrome, congestive heart failure/cardiomyopathy, and idiopathic geriatric anemia.

14. The method of claim 10 , wherein the anemia is due to impaired iron absorption or poor nutrition.

15. The method of claim 10 , wherein the anemia is associated with Crohn's Disease, gastric surgery, ingestion of drug products that inhibit iron absorption, or chronic use of calcium.

16. The method of claim 1 , wherein the disease, disorder, or condition is selected from among blood donation, hair loss, and attention deficit disorder.

17. The method of claim 1 , wherein administration of the single dosage is repeated.

18. The method of claim 1 , further comprising a second administration of said iron carbohydrate complex upon recurrence of at least one symptom of the disease, disorder, or condition.

19. The method of claim 18 , wherein the second administration is 3-4 days after the first administration.

20. The method of claim 18 , wherein the second administration is one week after the first administration.

21. The method of claim 1 , wherein the single dosage of elemental iron is at least about 1.0 grams.

22. The method of claim 21 , wherein the iron carbohydrate complex is administered intravenously.

23. The method of claim 1 , wherein the single dosage of elemental iron is at least about 1.5 grams.

24. The method of claim 1 , wherein the iron carbohydrate complex is administered intravenously.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2021
From: HELENEK, MARY JANE; TOKARS, MARC L.; LAWRENCE, RICHARD P.
To: LUITPOLD PHARMACEUTICALS, INC.
Reel/Frame 058183/0689 →
CHANGE OF NAME Recorded Nov 22, 2021
From: LUITPOLD PHARMACEUTICALS, INC.
To: AMERICAN REGENT, INC.
Reel/Frame 058220/0274 →
Continuity (9)
Continuation 16192681 · Nov 15, 2018
Continuation 15958930 · Apr 20, 2018
Division 14683415 · Apr 10, 2015
Continuation 14683415 · Apr 10, 2015
Continuation 13847254 · Mar 19, 2013
Continuation 12787283 · May 25, 2010
Continuation 11620986 · Jan 8, 2007
Provisional Application 60757119 · Jan 6, 2006
Related Publication 20200215096A1 · Jul 9, 2020
Cited By (2)
US 12,239,657 US 12,721,859